- NVRO Dashboard
- Financials
- Filings
-
Holdings
- Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
S-8 Filing
Nevro (NVRO) S-8Registration of securities for employees
Filed: 25 Feb 20, 5:10pm
As filed with the Securities and Exchange Commission on February 25, 2020
Registration No. 333-
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM S-8
REGISTRATION STATEMENT
UNDER
THE SECURITIES ACT OF 1933
NEVRO CORP.
(Exact name of registrant as specified in its charter)
|
|
|
Delaware |
| 56-2568057 |
(State or other jurisdiction of incorporation or organization) |
| (IRS Employer Identification No.) |
1800 Bridge Parkway
Redwood City, CA 94065
(Address of Principal Executive Offices) (Zip Code)
2014 Equity Incentive Award Plan
2014 Employee Stock Purchase Plan
(Full title of the plan)
D. Keith Grossman
Chief Executive Officer
Nevro Corp.
1800 Bridge Parkway
Redwood City, CA 94065
(Name and address of agent for service)
(650) 251-0005
(Telephone number, including area code, of agent for service)
|
|
|
Brian J. Cuneo, Esq. Latham & Watkins LLP 140 Scott Drive Menlo Park, CA 94025 (650) 328-4600 |
| Kashif Rashid, Esq. General Counsel Nevro Corp. 1800 Bridge Parkway Redwood City, CA 94065 (650) 251-0005 |
Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.
|
|
|
|
|
|
|
Large accelerated filer |
| ☒ |
| Accelerated filer |
| ☐ |
|
|
|
| |||
Non-accelerated filer |
| ☐ |
| Smaller reporting company |
| ☐ |
|
|
|
| |||
|
|
|
| Emerging growth company |
| ☐ |
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ☐
CALCULATION OF REGISTRATION FEE
|
|
|
|
|
|
|
|
|
| ||||||||
Title of Securities To Be Registered |
| Amount to be Registered (1) |
| Proposed Maximum Offering Price Per Share |
| Proposed Maximum Aggregate Offering Price |
| Amount of |
Common Stock, $0.001 par value |
| 1,261,774 (2) |
| $ 141.39 (3) |
| $178,402,225.86 |
| $23,156.61 |
Common Stock, $0.001 par value |
| 315,443 (4) |
| $ 141.39 (3) |
| $44,600,485.77 |
| $5,789.14 |
Total: |
| 1,577,217 |
|
|
| $223,002,711.63 |
| $28,945.75 |
| ||||||||
|
(1) | Pursuant to Rule 416(a) under the Securities Act of 1933, as amended (the “Securities Act”), this registration statement shall also cover any additional shares of the common stock of Nevro Corp. (the “Registrant”) that become issuable under the 2014 Equity Incentive Award Plan (the “2014 Plan”) and the 2014 Employee Stock Purchase Plan (the “ESPP”), by reason of any stock dividend, stock split, recapitalization or similar transaction effected without the Registrant’s receipt of consideration which would increase the number of outstanding shares of common stock. |
(2) | Represents the additional shares of common stock available for future issuance under the 2014 Plan resulting from an annual increase as of January 1, 2020. |
(3) | This estimate is made pursuant to Rule 457(c) and Rule 457(h) of the Securities Act solely for purposes of calculating the registration fee. The Proposed Maximum Offering Price Per Share for shares available for future grant is the average of the high and low prices for the registrant’s common stock as reported on The New York Stock Exchange on February 20, 2020, which is $141.39. |
(4) | Represents the additional shares of common stock available for future issuance under the ESPP resulting from an annual increase as of January 1, 2020. |
Proposed sale to take place as soon after the effective date of the
registration statement as awards under the plans are granted, exercised and/or vest.
EXPLANATORY NOTE
This Registration Statement on Form S-8 is being filed for the purpose of registering an additional 1,577,217 shares of the Registrant’s common stock issuable under the following employee benefit plans for which Registration Statements of the Registrant on Form S-8 (File Nos. 333-200145, 333-202857, 333-209816, 333-216206, 333-223159 and 333-229778) is effective: (i) the 2014 Equity Incentive Award Plan, as a result of the operation of an automatic annual increase provision therein, which added 1,261,774 shares of common stock, and (ii) the 2014 Employee Stock Purchase Plan, as a result of the operation of an automatic annual increase provision therein, which added 315,443 shares of common stock.
INCORPORATION BY REFERENCE OF CONTENTS OF REGISTRATION STATEMENTS ON
FORM S-8
Pursuant to Instruction E of Form S-8, the contents of the Registration Statements on Form S-8 filed with the Securities and Exchange Commission (File Nos. 333-200145, 333-202857, 333-209816, 333-216206, 333-223159 and 333-229778) are incorporated by reference herein.
EXHIBIT INDEX
|
|
|
|
|
|
|
|
|
|
|
|
|
Exhibit Number |
| Description of Document |
| Incorporated by Reference |
|
| Filed Herewith | |||||
|
| Form |
| Date |
| Number |
|
| ||||
|
|
|
|
|
| |||||||
4.1 |
|
| 8-K |
| 11/12/2014 |
|
| 3.1 |
|
|
| |
|
|
|
|
|
| |||||||
4.1(b) |
| Certificate of Amendment to Amended and Restated Certificate of Incorporation of Nevro Corp. |
| 8-K |
| 5/24/2019 |
|
| 3.1 |
|
|
|
|
|
|
|
|
| |||||||
4.2 |
|
| 8-K |
| 11/12/2014 |
|
| 3.2 |
|
|
| |
|
|
|
|
|
| |||||||
4.2(b) |
|
| 8-K |
| 5/24/2019 |
|
| 3.2 |
|
|
| |
|
|
|
|
|
| |||||||
4.3 |
|
| S-1/A |
| 10/27/2014 |
|
| 4.2 |
|
|
| |
|
|
|
|
|
| |||||||
5.1 |
|
|
|
|
|
|
|
|
|
| X | |
|
|
|
|
|
| |||||||
23.1 |
|
|
|
|
|
|
|
|
|
| X | |
|
|
|
|
|
| |||||||
23.2 |
|
|
|
|
|
|
|
|
|
| X | |
|
|
|
|
|
| |||||||
24.1 |
| Power of Attorney. Reference is made to the signature page to the Registration Statement. |
|
|
|
|
|
|
|
|
| X |
|
|
|
|
|
| |||||||
99.1(a)# |
|
| S-8 |
| 11/12/2014 |
|
| 99.2(a) |
|
|
| |
|
|
|
|
|
| |||||||
99.1(b)# |
|
| S-1/A |
| 10/10/2014 |
|
| 10.9(b) |
|
|
| |
|
|
|
|
|
| |||||||
99.1(c)# |
|
| S-1/A |
| 10/10/2014 |
|
| 10.9(c) |
|
|
| |
|
|
|
|
|
| |||||||
99.1(d)# |
|
| S-1/A |
| 10/10/2014 |
|
| 10.9(d) |
|
|
| |
|
|
|
|
|
| |||||||
99.2# |
|
| S-8 |
| 11/12/2014 |
|
| 99.3 |
|
|
|
# | Indicates management contract or compensatory plan. |
Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Redwood City, State of California, on this 25th day of February, 2020.
|
|
|
NEVRO CORP. | ||
|
| |
By: |
| /s/ D. KEITH GROSSMAN |
Name: |
| D. Keith Grossman |
Title: |
| Chief Executive Officer |
KNOW ALL PERSONS BY THESE PRESENTS, that each individual whose signature appears below constitutes and appoints D. Keith Grossman and Andrew H. Galligan, and each of them, as attorneys-in-fact, each with the power of substitution, for him or her and in his or her name, place and stead, in any and all capacities, to sign any and all amendments (including post-effective amendments) to this registration statement, and to file the same, with all exhibits thereto and all documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully to all intents and purposes as he or she might or could do in person, hereby ratifying and confirming all that such attorneys-in-fact and agents or any of them, or their substitute or substitutes, may lawfully do or cause to be done by virtue hereof.
Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.
Signature |
| Title |
| Date |
|
|
| ||
/s/ D. KEITH GROSSMAN D. Keith Grossman |
| President and Chief Executive Officer |
| February 25, 2020 |
|
|
| ||
/s/ ANDREW H. GALLIGAN Andrew H. Galligan |
| Chief Financial Officer (Principal Financial and Accounting Officer) |
| February 25, 2020 |
|
|
| ||
/s/ MICHAEL DEMANE Michael DeMane |
| Lead Director |
| February 25, 2020 |
|
|
| ||
/s/ FRANK FISCHER Frank Fischer |
| Director |
| February 25, 2020 |
|
|
| ||
/s/ WILFRED E. JAEGER Wilfred E. Jaeger, M.D. |
| Director |
| February 25, 2020 |
|
|
| ||
/s/ SHAWN T MCCORMICK Shawn T McCormick |
| Director |
| February 25, 2020 |
|
|
| ||
/s/ KEVIN O’BOYLE Kevin O’Boyle |
| Director |
| February 25, 2020 |
|
|
| ||
/s/ KAREN PRANGE |
| Director |
| February 25, 2020
|
Karen Prange |
| |||
|
|
| ||
/s/ BRAD H. VALE Brad H. Vale, Ph.D., D.V.M. |
| Director |
| February 25, 2020 |
|
|
| ||
/s/ ELIZABETH WEATHERMAN Elizabeth Weatherman |
| Director |
| February 25, 2020 |